The polymyxin antibiotic colistin is an antibiotic of last resort for the treatment of extensively drug-resistant Gram-negative bacteria, including carbapenemase-producing Enterobacteriaceae. The State of the World's Antibiotics report in 2015 highlighted South Africa (SA)'s increasing incidence of these 'superbugs' (3.2% of Klebsiella pneumoniae reported from SA were carbapenemase producers), and in doing so, underscored SA's increasing reliance on colistin as a last line of defence. Colistin resistance effectively renders such increasingly common infections untreatable.
In the 2015 State of the World's Antibiotics [1] report, an increasing incidence of extensively drug-resistant Gram-negative bacteria was highlighted for South Africa (SA), underscoring SA's increasing reliance on colistin as a last line of defence. Although colistin resistance was first reported in the Czech Republic in 1999 and was subsequently only reported sporadically, recent reports of increasing colistin resistance among clinical isolates, including from SA, are cause for alarm. [2, 3] Of particular concern is the emergence of colistin resistance among commonly encountered Enterobacteriaceae such as Klebsiella pneumoniae. Up to now, the mechanism of colistin resistance in SA isolates was due to changes in genes associated with complex alterations in the bacterial regulatory systems. [4] These genes were not readily transferrable between species.
Recent routine surveillance of antibiotic resistance in commensal Escherichia coli from food animals in China documented a major increase of colistin resistance due to a highly mobile, transferrable, plasmid-mediated colistin-resistance gene designated mcr-1. [5] They observed mcr-1 in E. coli isolates collected from 15% (78/523) of raw retail meat samples (chicken and pork) and 21% (166/804) of animals (pigs) during 2011 -2014. Of note, 1% (16/1 322) of clinical isolates from infected, hospitalised Chinese patients harboured mcr-1. The authors demonstrated trans fer of mcr-1 between E. coli strains, including strains with known epidemic potential, such as ST131. Furthermore, the plasmid could be passed to K. pneumoniae and even Pseudomonas aeruginosa strains.
Globally, the dissemination of mcr-1 among E. coli strains from feed animals and asymptomatic humans has now been reported from at least 17 countries. Recently, Dutch travellers to Asia (China, Thailand, Vietnam, Cambodia and Laos), North Africa (Tunisia) and South America (Peru, Bolivia and Colombia) were reported, after their travels, to have gastrointestinal colonisation with mcr-1-containing E. coli. [6] mcr-1 has also been detected among Salmonella spp. collected in 2012 -2013 from the French agricultural food sector and has been confirmed in Salmonella enterica serotype typhimurium cultured from food samples in Portugal. In addition, the mcr-1 gene has been identified in clinical isolates of K. pneumoniae and in association with carbapenemase genes. [7] Current situation in SA A countrywide surveillance programme of poultry operations revealed that colistin resistance in E. coli strains increased substantially in 2015, predominantly in the second half of the year. [8] It was surmised that this sudden increase was likely due to the selection of mcr-1-containing strains where colistin was being used. Subsequent analysis detected mcr-1 in 19/24 (79%) colistin-resistant cultures from the last quarter of 2015.
Of critical importance, mcr-1 has now been detected in clinical isolates of colistin-resistant E. coli from hospitalised (n=3) and outpatient-based (n=6) patients in SA. This has been con firmed by a specialised antibiotic resistance unit in Switzerland that performed confirmatory molecular studies including plasmid characterisation (submitted for publication). As depicted in Table 1 , mcr-1-positive, colistin-resistant E. coli was cultured from patients in two SA provinces. Except for one patient with an abscess, all the community-acquired cases presented to primary care with urinary tract infections. None was previously exposed to colistin. mcr-1 leads to raised colistin minimum inhibitory concentrations of 4 -8 mg/L. Four of the isolates coproduced an extended-spectrum β-lactamase (data not shown).
Implications for public health
The national and global significance of the sudden spread of MCR-1 and the attendant loss of colistin has profound public health implications, and confirms the continuum between colistin use in feed animals and colistin resistance in slaughtered animals, food for human consumption, colonised humans and infected patients. We join the international community in calling for tighter control of colistin use in animal health, including a ban on use for animal growth promotion and the need for an urgent review of its use in metaphylaxis in feed animals and directed therapy in companion animals. We also call for increased restriction of colistin use in patients. In this regard, redefined considerations for empirical and directed use of colistin are urgently warranted. Strict antibiotic stewardship is essential, including a mandatory loading dose of 12 million units, and use only in combination with at least one other agent.
